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Abstract
A new mutation in WT1 is described in a sporadic unilateral Wilms’ tumour consisting of a 17 bp duplication in exon 7
generating a stop codon. The second allele is either partially deleted or presents the same alteration. LOH analysis at 11p15.5
and at the 16q13-16q24.3 regions indicated retention of heterozygosity in the tumour DNA for the markers analysed. The
results are consistent with Knudson’s hypothesis and confirm that loss of function of WT1 contributes to the development of
at least some Wilms’ tumours. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
WT1 is one of the genes involved in Wilms’
tumour [1,2], a childhood malignancy of the kid-
ney occurring in a frequency of 1 in 10 000 live
births [3]. The gene is mainly expressed during the
development of the kidney and in genitourinary
structures [4]. It encodes a protein with four zinc
¢nger motifs which act both as a transcriptional sup-
pressor and as an activator of growth related genes
[5].
WT1 mutations in Wilms’ tumours are a rare
event, only detectable in 10^15% of the Wilms’ tu-
mours [6]. Of these, at least 69% [7] were shown to
carry inactivation of the second allele, following the
classic two-hit hypothesis [8]. Approx. 1^2% of
Wilms’ tumour patients have an associated AGR
(Aniridia, Genitourinary anomalies and mental Re-
tardation) syndrome and demonstrate intragenic mu-
tations in the remaining WT1 allele in the tumour [7].
In Wilms’ tumours associated with Denys-Drash syn-
drome which account for less than 1% of all tu-
mours, WT1 homozygosity/hemizygosity occurs in
almost all cases [9]. Therefore, it can be concluded
that complete inactivation of WT1 occurs in WT1
associated Wilms’ tumours.
Deletions and point mutations are among the most
frequent inactivating mutations of WT1. Tandem in-
sertions seem to be a more rare type of mutation
and, to our knowledge, only reported in four cases
[10^13]. Here, we describe a Wilms’ tumour patient
with a somatic mutation consisting of a tandem in-
sertion of 17 base pairs in exon 7 generating a stop
codon. This ¢nding provides further evidence for the
involvement of complete inactivation of WT1 in the
subset of Wilms’ tumours.
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2. Materials and methods
2.1. Patient
AGM, a male child aged 5 years, with normal
genitalia, developed a sporadic Wilms’ tumour of
the right kidney at the age of 5 years. Histological
analysis of the surgically resected sample revealed a
capsulated tumour without evidence of nuclear ana-
plasia, containing stroma and epithelial elements
such as tubules, microcysts and glomerular bodies.
No blastemal tissue was observed, probably due to
pre-operative chemotherapy treatment (S. Fleming,
pers. commun.).
2.2. Molecular analysis
Simultaneous DNA and RNA extraction was car-
ried out from fresh tumour or from para⁄n em-
bedded tissue, according to Santos and Oso¤rio Al-
meida [14]. DNA was obtained from peripheral
blood lymphocytes of the patient and his parents,
following described methods [15,16].
The search for WT1 mutations was carried out
using the polymerase chain reaction-single strand
conformation polymorphism (PCR-SSCP) of exons
2^10 of tumour DNA as previously described
[10,17]. Exon 1 was analysed as described by Hu¡
et al. [18].
Direct genomic sequencing of lymphocyte and tu-
mour DNA was performed after ampli¢cation, using
Dynabeads (Dynal, Merseyside, UK), essentially as
described by Hogg et al. [17].
PCR covering exons 7^9 of WT1 was carried out
in tumour DNA using the gene Amp XL PCR kit
(Perkin Elmer) and primers described by Baird et al.
[10].
The following conditions were used: 500 ng of
DNA, 150 pmole of each primer, 1.6 mM Mg2,
40 mM dNTP blend in a 50 Wl reaction volume.
Ampli¢cation was for 35 cycles at 95‡C for 1 min,
58‡C for 1 min and 72‡C for 5 min. Cycling was
preceded by 7 min at 95‡C, 1 min at 58‡C and fol-
lowed by 10 min at 72‡C. The PCR products were
analysed in 1% agarose gel electrophoresis.
Tumour mRNA analysis was performed by RT-
PCR (Pharmacia bulk ¢rst strand cDNA kit) with
primers for exons 1, 2, 6, 8 and 10 [10] and for
exon 4 (primers cD 5U4: 5P-GAC AAT TTA TAC
CAA ATG ACA TCC CC-3P and cD 3U4: 5P-CCC
TTT AAG GTG GCT CCT AAG TTC-3P), exon 7
(primers cD 5U7: 5P-GAT GTG CGA CGT GTG
CCT GGA G-3P and cD 3U7: 5P-CAG TGT GCT
TCC TGC TGT GCA A TC-3P), exon 9 (primer cD
3U9: 5P-CTG TAT GAG TCC TGG TGT GGG
TC-3P) and 3P-UTR (primers localized 934 bp away
from the gene, see [19]).
Ampli¢cation of exons 1^2, 2^6, 6^8 and 8^10 was
carried out according to Baird et al. [10]. Conditions
for ampli¢cation of exons 4^7, 4^9 and 7^9 were the
following: 1/30 of the ¢rst strand cDNA product
were added to the PCR reaction mixture (10 mM
Tris-HCl pH 8.8, 50 mM KCl, 1.5 mM Mg Cl2,
0.1% Triton X-100, Taq DNA polymerase, Pharma-
cia), and subjected to 45 cycles of ampli¢cation 3 min
at 95‡C, 1.5 min at 62‡C and 6 min at 72‡C. Cycling
was preceded by 7 min at 95‡C, 2 min at 62‡C and
followed by 10 min at 72‡C. All PCR products were
analysed in 4% agarose gel electrophoresis. Ampli¢-
cation of exon 4^3P-UTR region was with the gene
Amp XL PCR kit in the conditions described above,
but with 1/10 of the ¢rst strand cDNA product. Elec-
trophoresis was in 1% agarose gel. In parallel, PCR
was performed on tumour cDNA for the OCRL
(oculocerebrorenal) gene with primers which amplify
several exons from the middle part of the gene, as a
control for the presence of cDNA in the sample [20].
LOH screening was performed at genomic regions
suggested to harbour additional loci implicated in
Wilms’ tumorigenesis, namely 11p15.5 and 16q13-
16q24.3 [21,22].
LOH analysis for 11p15 was performed with prim-
ers for IGF2 [23] and for GQ- and AQ-globin [24].
LOH analysis for 16q was performed by PCR using
described primers for microsatellites [25]. These in-
cluded D16S408, D16S514, D16S496, D16S512,
D16S515, D16S516, D16S507, D16S402, D16S520,
D16S413. PCR was performed in a reaction volume
of 25 Wl including [K-32P]dCTP. The following bu¡-
ers were used: 10 mM Tris-HCl, pH 8.8, 50 mM
KCl, 1.5 mM MgCl2, 0.1% Triton X-100 for primers
D16S514, D16S496, D16S512, D16S515, D16S516,
D16S507, D16S511, D16S520, D16S413; 20 mM
Tris-HCl, pH 8.55, 16 mM (NH4)2SO4, 150 Wg/ml
BSA, 2.5 mM MgCl2 for primer D16S408; 20 mM
Tris-HCl, pH 8.5, 16 mM (NH4)2SO4, 150 Wg/ml
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BSA, 1.0 mM MgCl2 for primer D16S518; 50 mM
KCl, 10 mM Tris-HCl, pH 9, 0.1% Triton X-100,
2.5 mM MgCl2 for primer D16S402. The PCR prod-
ucts were analysed on a denaturing (7 M urea) 6%
polyacrylamide gel. The gel was dried and autoradio-
graphed at 380‡C.
3. Results
3.1. Cytogenetic and FISH analysis
Cytogenetic analysis of peripheral blood lympho-
cytes and of primary tumour cell cultures revealed a
normal 46,XY karyotype. FISH analysis on cell sus-
pensions prepared from para⁄n embedded tumour
sample with the alphoid probe (pL11A, see [26]),
showed that both 11 chromosomes were present in
the tumour cells.
3.2. Molecular analysis
Individual PCR products of exons 2^10 of WT1 in
the tumour DNA indicated a larger than expected
fragment in exon 7. SSCP analysis of exon 7 showed
a mobility shift in the banding pattern (Fig. 1). Di-
rect sequence analysis of this exon revealed a 17 bp
insertion consisting of a tandem duplication of the
sequence GTGTGCCTGGAGTAGCC, after the
27th nucleotide of exon 7 (Fig. 2). The insertion cre-
ates a one base pair frameshift resulting in the gen-
eration of a stop codon 12 nucleotides downstream
(Fig. 2). SSCP and sequencing patterns of exon 7
showed the exclusive presence of the mutated allele
(Figs. 1 and 3). Sequencing of exon 7 in lymphocyte
DNA revealed only the wild type allele (Fig. 3).
No transcript was detected in tumour cDNA am-
pli¢ed from exons 1^2, 2^6, 4^7, 4^9, 7^9, 8^10 and
from exon 4^3P-UTR. However, mRNA was present,
since the OCRL cDNA could be ampli¢ed from the
same sample (not shown).
Search for LOH in 11p15.5 and 16q indicated re-
tention of heterozygosity in the tumour DNA.
4. Discussion
In the present study, a somatic mutation consisting
of a 17 bp duplication in exon 7 of WT1, generating
a stop codon, was found in a sporadic unilateral
Wilms’ tumour. Only the mutant allele was detected
in SSCP and DNA sequencing analysis. In situ hy-
Fig. 1. PCR-SSCP analysis of WT1 exon 7 in tumour DNA
from the patient (lane 1), compared with ¢ve other tumour
samples (lanes 2^6). Lanes 2, 3, 5 and 6 reveal normal patterns.
All bands in lane 1 are upshifted, suggesting an insertion.
Fig. 2. Illustration of part of the sequence of intron 6-exon 7
of WT1 from blood and tumour DNA of the patient, showing
the 17 bp insertion in the tumour DNA. Insertion begins at *
and is a direct repeat of the underlined sequence. Flanking di-
rect repeats are signaled in boxes. Inverted repeats are limited
by v. Capital letters, exon; lowercase letters, intron.
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bridization revealed the presence of both chromo-
somes 11.
The presence of a constitutional or a somatic dele-
tion encompassing exon 7, undetected by our meth-
ods on the basis of PCR analysis, cannot be ex-
cluded. The limited quantities of blood and tumour
DNA precluded its analysis by Southern blotting.
RNA analysis failed to reveal any transcripts from
tumour cells. The failure to detect any abnormal
transcripts in the tumour tissue may be due to
mRNA instability. It is known that stop codons
may cause not only early termination of translation
and exon skipping [27], but also rapid mRNA decay
[28].
The fact that a tandem insertion was detected in
exon 7 of WT1 deserves further comment. To our
knowledge, only four tandem insertional mutations
have been described in Wilms’ tumour and two of
them in or near exon 7 [10,13]. On the other hand,
tandem insertions in exon 7 have been reported as a
preferential event among WT1 mutations in a series
of patients with leukaemia [29].Therefore, exon 7
may be particularly prone to this type of mutation.
Like in other genes [30,31], most insertions or dele-
tions found in WT1 have been related to inverted or
direct repeats present in the surrounding DNA [18].
In the tumour DNA, we observe small tetranucleo-
tide £anking direct repeats (Fig. 2). An inverted re-
peat is also observed (Fig. 2), possibly leading to the
formation of a hairpin loop. However, the free en-
ergy of 33.8 kcal/mole involved in the loop forma-
tion (DNAsis 5.00 version, 1987) seems rather weak,
leaving a slipped mispairing mechanism as the most
likely one to explain this insertion.
In the present case, in which inactivation of both
alleles of WT1 took place, retention of heterozy-
gosity in known critical regions for Wilms’ tumour,
11p15.5 and 16q13-24.3, was veri¢ed for the markers
examined. Although this may suggest that inactiva-
tion of both copies of WT1 would be su⁄cient for
Wilms’ tumorigenesis, additional search for LOH in
critical regions in other Wilms’ tumours with WT1
inactivation is needed to con¢rm this hypothesis.
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